Toward a Common Proteomics Platform - ACS Publications

This adds to the challenge for a body such as HUPO, because international, multicenter ... Department of Chemistry ... Pfizer Global Research & Develo...
0 downloads 0 Views 46KB Size
EDITOR-IN-CHIEF

editor ial

William S. Hancock Barnett Institute and Department of Chemistry Northeastern University 360 Huntington Avenue 341 Mugar Bldg. Boston, MA 02115 617-373-4881; fax 617-373-2855 [email protected]

ASSOCIATE EDITORS

Joshua LaBaer Harvard Medical School

György Marko-Varga

Toward a Common Proteomics Platform

AstraZeneca and Lund University

CONSULTING EDITOR

Jeremy Nicholson Imperial College London

EDITORIAL ADVISORY BOARD

Ruedi H. Aebersold ETH Hönggerberg

Leigh Anderson Plasma Proteome Institute

Ettore Appella U.S. National Cancer Institute

Rolf Apweiler European Bioinformatics Institute

Ronald Beavis Manitoba Centre for Proteomics

John J. M. Bergeron McGill University

Richard Caprioli Vanderbilt University School of Medicine

Christine Colvis U.S. National Institutes of Health

Catherine Fenselau University of Maryland

Daniel Figeys University of Ottawa

Sam Hanash

he first U.S. HUPO meeting was held in Washington, D.C., in March and was a significant success, with some 300 delegates and a three-day science program. It is not my goal to give a meeting report but rather to discuss some issues related to the activities of HUPO. It is clear from publications in proteomics journals as well as the meeting that the field has made substantial progress. Nevertheless, one can also see that many challenges remain, especially with the most complex samples, such as plasma. The boundary conditions range from the targeted study of limited protein mixtures to ambitious global studies. At either extreme, one can ask whether a consensus is beginning to emerge about a common platform for studies. I think most researchers in the field would say that a consensus has not been reached and that rapid evolution in methodology and instrumentation continues. This adds to the challenge for a body such as HUPO, because international, multicenter studies take time and the early phases are largely superseded by progress in methodology. As I see it, though, the main purpose of such meetings is to encourage a diverse group of technologists to coalesce around a platform that can be used for large-scale proteomics studies. At present, I see a lively set of opinions being presented at proteomics meetings. The energetic discussion is heartening, but we should remember that these views need to be subjected to the scrutiny of international studies. This type of examination was important in the sequencing of the human genome and will be even more so in this case because of the proteome’s enormous complexity. So keep up the good work, and be ready to stay the long course.

T

Fred Hutchinson Cancer Research Center

Stanley Hefta Bristol-Myers Squibb

Denis Hochstrasser University of Geneva

Donald F. Hunt University of Virginia

Barry L. Karger Northeastern University

Daniel C. Liebler Vanderbilt University School of Medicine

Lance Liotta U.S. National Cancer Institute

Matthias Mann University of Southern Denmark

David Muddiman Mayo Clinic College of Medicine

Gilbert S. Omenn University of Michigan

Aran Paulus Bio-Rad Laboratories

Jasna Peter-Katalini´c University of Muenster

Emanuel Petricoin George Mason University

Ruth VanBogelen Pfizer Global Research & Development

Peter Wagner Zyomyx

Keith Williams Proteome Systems

Qi-Chang Xia Shanghai Institute of Biochemistry

John R. Yates, III The Scripps Research Institute

© 2005 American Chemical Society

Journal of Proteome Research • Vol. 4, No. 2, 2005

213